UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma (original) (raw)
The role of epigenetics in malignant pleural mesothelioma
Roland Hubaux
Lung Cancer, 2013
View PDFchevron_right
Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets
Oluf Dimitri Røe
Lung Cancer, 2010
View PDFchevron_right
Important recent insights into the genetics and biology of malignant pleural mesothelioma
Marc Ladanyi
Annals of cardiothoracic surgery, 2012
View PDFchevron_right
Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment
Didier Jean
Archives of Pathology & Laboratory Medicine, 2012
View PDFchevron_right
EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma
LOREDANA MIGLIORE
International Journal of Molecular Sciences, 2020
View PDFchevron_right
SFRPTumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma
Yuen Yau Cheng
Disease Markers, 2017
View PDFchevron_right
Supplementary Figure 1 from Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma
John Godleski
2023
View PDFchevron_right
UHRF1‐mediated tumor suppressor gene inactivation in nonsmall cell lung cancer
George Xinarianos
Cancer, 2011
View PDFchevron_right
KRAS signaling in malignant pleural mesothelioma
ÖZGECAN Kayalar
EMBO Molecular Medicine, 2021
View PDFchevron_right
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets
Tullio Florio
Biochemical Pharmacology, 2011
View PDFchevron_right
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
Ralph Schmid
Frontiers in Oncology, 2020
View PDFchevron_right
Molecular Targets in Malignant Pleural Mesothelioma Treatment
Giulia Pasello
Current Drug Targets, 2009
View PDFchevron_right
hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma
Chandra Goparaju
Cancer Research, 2010
View PDFchevron_right
Genomic mapping identifies multiple therapeutic pathways in malignant mesothelioma
Deborah Morris-Rosendahl
View PDFchevron_right
Therapies currently in Phase II trials for malignant pleural mesothelioma
Daniela D Tavian
Expert Opinion on Investigational Drugs, 2013
View PDFchevron_right
Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives from Preclinical and Clinical Studies
Antonio Daga, Federica Barbieri
View PDFchevron_right
Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS
Sang-we Kim
Translational oncology, 2018
View PDFchevron_right
844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies
Francesca Piazzini
Late-breaking abstracts, 2020
View PDFchevron_right
Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis
M. Falleni
The American Journal of Pathology, 2009
View PDFchevron_right
Integrated Profiling Reveals a Global Correlation between Epigenetic and Genetic Alterations in Mesothelioma
John Godleski
Cancer Research, 2010
View PDFchevron_right
Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Aarti Mathur
Clinical Cancer Research, 2011
View PDFchevron_right
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach
Nasreen Najmunnisa
ajcr.us
View PDFchevron_right
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
Francesca Piazzini
Epigenomes, 2021
View PDFchevron_right
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma
H. Brahmbhatt
American journal of respiratory and critical care medicine, 2015
View PDFchevron_right
Expression status of candidate genes in mesothelioma tissues and cell lines
Silvia Pellegrini
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015
View PDFchevron_right
Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells
Hiroyuki Kohara
Lung Cancer, 2019
View PDFchevron_right
Expression and activity of eIF6 trigger Malignant Pleural Meso thelioma growth in vivo
Luciano Mutti
2015
View PDFchevron_right
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126
Annette Alleva
Anticancer …, 2006
View PDFchevron_right
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Michele Carbone
Journal of Thoracic Oncology, 2018
View PDFchevron_right
The Genes–Stemness–Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints
Antonella Di Gennaro
International Journal of Molecular Sciences
View PDFchevron_right
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Massimiliano Mazza
Frontiers in Oncology
View PDFchevron_right
KRAS signalling in malignant pleural mesothelioma
Sophia Antimisiaris
bioRxiv, 2020
View PDFchevron_right